The Academy of Managed Care Pharmacy – University of Minnesota Student Chapter is committed to keeping the student body educated and knowledgeable about new drug therapies and how these therapies will impact the current U.S. Health Care System.

*If you have trouble viewing the monographs, try resizing your browser window.*

Drug Monographs for New Novel Drug Approvals:

Solriamfetol (SUNOSI) – Approved March 20, 2019

Brexanolone (ZULRESSO) – Approved March 19, 2019

Prucalopride (MOTEGRITY) – Approved December 14, 2018

Larotrectinib (VITRAKVI) – Approved November 28, 2018

Amifampridine (FIRDAPSE) – Approved November 28, 2018 

Rifamycin (AEMCOLO) – Approved November 16, 2018

Baloxavir marboxil (XOFLUZA) – Approved October 24, 2018

Galcanezumab-gnlm (EMGALITY) – Approved September 27, 2018

Lanadelumab-flyo (TAKHZYRO) – Approved August 23, 2018

Segesterone acetate and ethinyl estradiol (ANNOVERA) – Approved August 10, 2018

Migalastat (GALAFOLD) – Approved August 10, 2018

Fish oil triglycerides (OMEGAVEN) – Approved July 27, 2018

Elagolix (ORILISSA) – Approved July 23, 2018

Tafenoquine (KRINTAFEL) – Approved July 20, 2018

Tecovirimat (TPOXX) – Approved July 13, 2018

Encorafenib and Binimetinib (BRAFTOVI and MEKTOVI) – Approved June 27, 2018

Cannabidiol (EPIDIOLEX) – Approved June 25, 2018

Plazomicin (ZEMDRI) – Approved June 25, 2018

Moxidectin (MOXIDECTIN) – Approved June 13, 2018

Niraparib (ZEJULA) – Approved March 27, 2017

Avelumab (BAVENCIO) – Approved March 23, 2017

Ribociclib (KISQALI) – Approved March 13, 2017

Telotristat ethyl (XERMELO) – Approved February 28, 2017

Brodalumab (SILIQ) – Approved February 15, 2017

Deflazacort (EMFLAZA) – Approved February 9, 2017

Etelcalcetide (PARSABIV) – Approved February 7, 2017

Plecanatide (TRULANCE) – Approved January 19, 2017

Nusinersen (SPINRAZA) – Approved December 23, 2016

Rucaparib (RUBRACA) – Approved December 19, 2016

Crisaborole (EUCRISA) – Approved December 14, 2016

Bezlotoxumab (ZINPLAVA) – Approved October 21, 2016

Olaratumab (LARTRUVO) – Approved October 19, 2016

Eteplirsen (EXONDYS 51) – Approved September 19, 2016

Drug Monographs for New Bio-similar Drug Approvals:

Adalimumab-atto (AMJEVITA) – Approved September 23, 2016